Teva Pharmaceutical Industries Limited (TEVA)
TEVA trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/0001193125-26-034532-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TEVA on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0000818686 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $17.3B |
| Net income | $1.4B |
| Operating income | $2.2B |
| Net margin | 8.2% |
| Operating margin | 12.5% |
| Revenue growth | +4.3% |
| Cash | $3.6B |
| Total assets | $40.7B |
| P/E (computed) | 35.2× |
| P/S (computed) | 2.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $4.1B cash; operating cash flow $442.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,166,826,784 (2026-09-30); 1,147,282,512 a year earlier; 1,120,971,202 three years earlier. | Cover page 2026-09-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns | Latest 2026-09-11 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-09-14 |
| Auditor | Kesselman & Kesselman C.P.A.s, Tel-Aviv, Israel | PCAOB Form AP 2026-02-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $112.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $4.4B | $233.0M | $241.0M | $4.1B | $4.0B | $14.0B | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $4.1B | -$576.0M | $411.0M | $3.7B | $4.5B | $14.1B | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $4.0B | $369.0M | -$40.0M | $3.7B | $2.6B | $14.1B | 10-Q 2026-04-29 |
| Q4 2025 2025-12-31 | $1.5B | $480.0M | $1.2B | $3.6B | $1.8B | $14.0B | 10-K 2026-02-03 |
| Q3 2025 2025-09-30 | $4.5B | $433.0M | $369.0M | $2.2B | $1.0M | $16.8B | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $4.2B | $282.0M | $227.0M | $2.2B | $441.0M | $16.6B | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $3.9B | $214.0M | -$105.0M | $1.7B | $398.0M | $16.6B | 10-Q 2026-04-29 |
| Q4 2024 2024-12-31 | $4.2B | -$217.0M | $575.0M | $3.3B | $1.8B | $16.5B | 10-K 2026-02-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-11 |
| Latest annual report | 10-K | 2026-02-03 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report FORM 8-K | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-03-31 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.4% |
| 1 month | +7.9% |
| 3 months | +21.9% |
| Year to date | +42.6% |
| 1 year | +74.2% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ONC | BeOne Medicines Ltd. | $411.29 | -1.26% | $47.0B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $68.53 | -1.13% | $39.3B |
| TAK | Takeda Pharmaceutical Company Limited | $21.59 | +0.75% | $68.2B |
| ZTS | Zoetis Inc. | $84.39 | +0.68% | $34.3B |
| GMAB | Genmab A/S ADS | $51.57 | +0.39% | $32.2B |
| ROIV | Roivant Sciences Ltd. Common Shares | $38.61 | -2.33% | $28.0B |
| INSM | Insmed Incorporated | $122.88 | +1.42% | $27.0B |
| REGN | Regeneron Pharmaceuticals Inc. | $952.40 | -0.32% | $98.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier